Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab in Patients With Recurrent Glioblastoma

Trial Profile

A Phase 1b, Open-Label, Safety and Tolerability Study of TTAC-0001 in Combination With Pembrolizumab in Patients With Recurrent Glioblastoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olinvacimab (Primary) ; Pembrolizumab (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors PharmAbcine
  • Most Recent Events

    • 31 May 2020 Results assessing safety and tolerability of TTAC-0001 in combination with pembrolizumab in patients with recurrent glioblastoma, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Apr 2020 Interim results, presented in a PharmAbcine media release.
    • 03 Apr 2020 According to an PharmAbcine media release, the abstract summarizing interim data on the trial, has been accepted at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top